| John Covington Boswell, MD | |
|
255 Baptist Blvd Ste 402, Columbus, MS 39705-2006 | |
| (662) 244-2550 | |
| Not Available |
| Full Name | John Covington Boswell |
|---|---|
| Gender | Male |
| Speciality | Sleep Medicine |
| Experience | 21 Years |
| Location | 255 Baptist Blvd Ste 402, Columbus, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316991219 | NPI | - | NPPES |
| 09089710 | Medicaid | MS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Memorial Hospital Golden Triangle Inc | Columbus, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Memorial Medical Group, Inc. | 5193610228 | 433 |
News Archive
Researchers at The University of Texas Medical Branch at Galveston have found that cancer survivors who were diagnosed at adolescent and young adult ages are more likely to be current cigarette smokers than people who have not had cancer. The findings of this study are currently available in Cancer.
With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.
Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.
Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.
› Verified 7 days ago
| Entity Name | Baptist Memorial Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306089206 PECOS PAC ID: 5193610228 Enrollment ID: O20101011000028 |
News Archive
Researchers at The University of Texas Medical Branch at Galveston have found that cancer survivors who were diagnosed at adolescent and young adult ages are more likely to be current cigarette smokers than people who have not had cancer. The findings of this study are currently available in Cancer.
With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.
Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.
Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.
› Verified 7 days ago
| Entity Name | Hospitalist Services Of Meridian Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639629777 PECOS PAC ID: 3274818042 Enrollment ID: O20170316002383 |
News Archive
Researchers at The University of Texas Medical Branch at Galveston have found that cancer survivors who were diagnosed at adolescent and young adult ages are more likely to be current cigarette smokers than people who have not had cancer. The findings of this study are currently available in Cancer.
With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.
Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.
Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Covington Boswell, MD 965 Ridge Lake Blvd Bldg Ste 103, Memphis, TN 38120-9401 Ph: () - | John Covington Boswell, MD 255 Baptist Blvd Ste 402, Columbus, MS 39705-2006 Ph: (662) 244-2550 |
News Archive
Researchers at The University of Texas Medical Branch at Galveston have found that cancer survivors who were diagnosed at adolescent and young adult ages are more likely to be current cigarette smokers than people who have not had cancer. The findings of this study are currently available in Cancer.
With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.
Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.
Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.
› Verified 7 days ago
Fakhri Dalati, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 5th St N, Columbus, MS 39705 Phone: 662-244-2042 Fax: 662-244-2041 | |
Dr. Connie Harris Scurti, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 301, Columbus, MS 39705 Phone: 662-244-1705 Fax: 662-227-4301 | |
Dr. Michael R Duckworth, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 2225 5th St N, Columbus, MS 39705 Phone: 662-327-0197 Fax: 662-327-5660 | |
Michael J Boland, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd, Suite 402, Columbus, MS 39705 Phone: 662-240-1412 Fax: 662-240-1949 | |
Dr. Madhukar Saran, M.D Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 824 Alabama St, Columbus, MS 39702 Phone: 662-244-0391 Fax: 662-244-0395 | |
Dr. Paul J Scurti, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 301, Columbus, MS 39705 Phone: 662-244-1705 Fax: 662-227-4301 | |
Wail Alnas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 345 Baptist Blvd, Columbus, MS 39705 Phone: 662-244-2288 Fax: 662-244-2763 |